These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. van Kempen LC; Leenders WP Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306 [TBL] [Abstract][Full Text] [Related]
6. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Rosen LS Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis. Haspel HC; Scicli GM; McMahon G; Scicli AG Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307 [TBL] [Abstract][Full Text] [Related]
8. Vascular targeting and the inhibition of angiogenesis. Bicknell R Ann Oncol; 1994; 5 Suppl 4():45-50. PubMed ID: 7520262 [TBL] [Abstract][Full Text] [Related]
9. [New molecular target of cancer therapy--angiogenesis regulator VEGF]. Toi M; Ueno T; Tominaga T Gan To Kagaku Ryoho; 1997 Dec; 24(15):2202-6. PubMed ID: 9422062 [TBL] [Abstract][Full Text] [Related]
10. Advances in the use of angiogenesis inhibitors in cancer. Pinedo HM Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080 [No Abstract] [Full Text] [Related]
11. Angiogenesis-research frontiers. A basic science conference of the New York Academy of Medicine. Sepp-Lorenzino L; Pan BS Expert Opin Investig Drugs; 2000 Apr; 9(4):929-35. PubMed ID: 11185425 [TBL] [Abstract][Full Text] [Related]